Related Experiment Video
Updated: Jul 20, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Phosphorylated MAPK11 promotes the progression of clear cell renal cell carcinoma by maintaining RUNX2 protein
Xiandong Song1, Changming Dong1, Xiaojun Man1
1Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Abstract:
Previous studies have demonstrated that mitogen-activated protein kinase 11 (MAPK11) functions as an important point of integration in signalling transduction pathways and controlling endocellular processes, including viability of cells, differentiation, proliferation and apoptosis, through the sequence phosphorylation of the substrate protein Ser/Thr kinase protein cascade. Though MAPK 11 plays an important role in various tumours, especially in the invasive and metastatic processes, its expression and molecular mechanism in clear cell renal cell carcinoma (ccRCC) remain unclear. Runt-associated transcription factor 2 (RUNX2), a main transcription factor for osteoblast differentiation and chondrocyte maturation, has high expression in a number of tumours. In this study, the mRNA and protein levels of targeted genes in ccRCC tissues and adjacent tissues are analysed using the Cancer Genome Atlas (TCGA) database and western blotting. The ccRCC cell proliferation was measured with colony formation and EdU assay, and cell migration was examined through transwell assay. The interactive behaviour between proteins was detected with immunoprecipitation. Half-life period of RUNX2 protein was measured with cycloheximide chase assay. The results of the study indicated overexpression of MAPK11 and RUNX2 in ccRCC tissues and cell lines. MAPK11 and RUNX2 promoted the ccRCC cell proliferation and migration. Additionally, physical interaction took place between RUNX2 and P-MAPK11, which functioned to sustain the stability of RUNX2 protein. The high expression of RUNX2 could neutralize the functional degradation in MAPK11. And the outcomes of the study suggest that the P-MAPK11/RUNX2 axis may be used as a potential therapeutic target of ccRCC.
Insights
Mitogen-activated protein kinase 11 (MAPK11) and Runt-associated transcription factor 2 (RUNX2) are overexpressed in clear cell renal cell carcinoma (ccRCC). This P-MAPK11/RUNX2 axis promotes ccRCC progression and may be a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Mitogen-activated protein kinase 11 (MAPK11) is crucial in cell signaling pathways, influencing cell viability, differentiation, proliferation, and apoptosis.
- While MAPK11 is implicated in various cancers, its specific role in clear cell renal cell carcinoma (ccRCC) remains largely unelucidated.
- Runt-associated transcription factor 2 (RUNX2) is a key transcription factor in osteoblast and chondrocyte development, with known overexpression in several tumor types.
Purpose of the Study:
- To investigate the expression and molecular mechanisms of MAPK11 and RUNX2 in clear cell renal cell carcinoma (ccRCC).
- To determine the functional roles of MAPK11 and RUNX2 in ccRCC cell proliferation and migration.
- To explore the interaction between MAPK11 and RUNX2 and its impact on ccRCC progression.
Main Methods:
- Analysis of mRNA and protein levels in ccRCC tissues versus adjacent tissues using The Cancer Genome Atlas (TCGA) database and western blotting.
- Assessment of ccRCC cell proliferation via colony formation and EdU assays, and cell migration using Transwell assays.
- Detection of protein interactions via immunoprecipitation and measurement of RUNX2 protein stability using cycloheximide chase assays.
Main Results:
- Overexpression of both MAPK11 and RUNX2 was observed in ccRCC tissues and cell lines.
- MAPK11 and RUNX2 significantly promoted ccRCC cell proliferation and migration.
- A physical interaction between RUNX2 and phosphorylated MAPK11 (P-MAPK11) was identified, stabilizing RUNX2 protein and potentially counteracting MAPK11 degradation.
Conclusions:
- The P-MAPK11/RUNX2 axis is upregulated in ccRCC and drives tumor progression.
- The interaction between P-MAPK11 and RUNX2 enhances RUNX2 stability, contributing to ccRCC development.
- Targeting the P-MAPK11/RUNX2 axis presents a potential therapeutic strategy for ccRCC.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules